Class Action Lawsuit Against Regeneron Pharmaceuticals
Pomerantz LLP has recently initiated a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This legal action raises significant concerns regarding the company's business practices and potential securities fraud.
Reasons Behind the Lawsuit
The class action centers on whether Regeneron and its officers engaged in unlawful activities impacting investors. This lawsuit aims to address allegations that the company may have participated in fraudulent behavior, particularly related to the reporting of financial data and sales practices.
Investor Information
Investors who purchased or acquired Regeneron securities during the specified Class Period are encouraged to consider securing their position as Lead Plaintiff in the lawsuit. Those who are interested must act before the deadline, which is set for a specified date. While the exact date isn't included, it is imperative that affected parties respond promptly to express their interest.
Allegations from the U.S. Department of Justice
A significant matter contributing to the class action arose when the U.S. Department of Justice (DOJ) filed a complaint against Regeneron under the False Claims Act. The complaint alleged that the company failed to disclose extensive discounts sent to drug distributors through reimbursed credit card fees.
Impact on Stock Price
This revelation led to a notable decline in Regeneron’s stock price, demonstrating the potential impact of the allegations on investors. Following this news, Regeneron’s stock dropped considerably during trading sessions, reflecting investors' concerns about the company's practices.
Recent Financial Results
In addition to the DOJ allegations, Regeneron reported disappointing financial results for the third quarter, indicating stagnation in U.S. sales for their leading products, Eylea and Eylea HD. The slow growth of just 3% in sales compared to the previous year, coupled with reports of missing expected revenue targets, has raised further questions about the company’s performance.
Market Reactions
This disappointing financial news also resulted in a significant dip in stock value. Investors reacted swiftly, highlighting their anxiety over the company's future prospects and financial integrity.
The Role of Pomerantz LLP
Pomerantz LLP has a profound reputation for its efforts in corporate and securities litigation, representing shareholders in cases of corporate misconduct. Founded by Abraham L. Pomerantz, the firm has dedicated over 85 years to advocating for victims of securities fraud, ensuring their rights are protected.
Encouraging Affected Investors to Act
If you believe your investment in Regeneron Pharmaceuticals might have been impacted by these recent events, contacting Pomerantz LLP or legal counsel is recommended to explore your options. The firm continues to seek justice for investors harmed by fiscal improprieties.
Frequently Asked Questions
What is the class action lawsuit about?
The class action lawsuit against Regeneron Pharmaceuticals pertains to allegations of securities fraud and misleading business practices.
How can investors join the class action?
Interested investors who purchased Regeneron securities during the Class Period must act quickly to secure a position as Lead Plaintiff.
What were the financial results reported by Regeneron?
Regeneron reported a mere 3% increase in U.S. sales, with quarterly sales for Eylea HD falling short of analyst expectations.
What impact did the DOJ complaint have on Regeneron's stock?
The DOJ's allegations resulted in a notable decline in Regeneron's stock price over several trading sessions, reflecting investors' concerns over the viability of the company.
What is the history of Pomerantz LLP?
Pomerantz LLP is renowned for its commitment to protecting shareholder rights, having pioneered the field of securities class actions for over 85 years.
